Delic to Acquire Ketamine Wellness Centers Inc, Becoming Largest Psychedelic Wellness Chain in United States

Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform today announced it has entered into a binding merger agreement (the “Merger Agreement”) with Ketamine Wellness Centers Arizona LLC (“KWC”). KWC is a limited liability corporation formed under the laws of Arizona, which operates 10 ketamine infusion treatment clinics, across Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas, and Washington. KWC is the largest national chain of ketamine infusion clinics in the United States and will add to Delic’s existing portfolio of two clinics operated by Ketamine Infusion Centers in California and Arizona.

Enveric Biosciences Announces Closing of MagicMed Industries Acquisition

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-centric biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced the closing of its acquisition of MagicMed Industries Inc. (“MagicMed”), a privately-held biotechnology company focused on creating a library of novel derivative psychedelic molecules such as psilocybin, N,N-dimethyltryptamine (DMT) and other molecular derivatives with applications across multiple indications, in an all-stock transaction.

Infinity BiologiX Acquires Roylance Pharma

IBX, a global leader in biobanking, bioprocessing and analytics, has acquired UK based biospecimen storage specialists Roylance Pharma. Roylance Pharma are UK based specialists in biobanking and stability storage of pharmaceutical and biological samples with combined experience of over 50 years specifically in sample storage services. Processes have been built from the ground up with state-of-the-art facilities, validation, SOP’s and quality systems.

Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) (“Xeris”) announced Tuesday that its stockholders have voted to approve the previously announced proposed acquisition of Strongbridge Biopharma plc (NASDAQ: SBBP) (“Strongbridge”) by Xeris. The acquisition was previously approved by Strongbridge shareholders. Upon close of the acquisition, the business of Xeris and Strongbridge will be combined under an entity called Xeris Biopharma Holdings, Inc.

Sanofi Completes Acquisition of Translate Bio

Sanofi announced today the completion of its acquisition of Translate Bio, further accelerating the company’s efforts to develop transformative vaccines and therapies using mRNA technology. The acquisition adds a critical pillar to the company’s mRNA Center of Excellence which aims to unlock the potential of next-generation mRNA vaccines and other strategic areas such as immunology, oncology, and rare diseases.

AzurRx BioPharma Announces Acquisition of First Wave Bio

AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has entered a definitive agreement to acquire First Wave Bio, Inc. (“First Wave Bio”) in a stock and cash transaction valued at $229 million, including certain development, regulatory and sales milestones. First Wave Bio is a clinical-stage biotechnology company specializing in the development of novel, gut-targeted, small molecule therapies for auto-immune inflammatory bowel diseases (IBD) and other serious conditions.

AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies against High-Value Targets

AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced it has acquired TetraGenetics, Inc. (TetraGenetics), a biotechnology company with a proprietary platform for generating recombinant human ion channels and other transmembrane proteins, in an all-cash transaction that includes an upfront payment, the potential for payments based on the achievement of technical milestones, and additional development and commercial milestone payments related to successfully developed therapeutics.

Clarus Therapeutics Closes Transaction with Blue Water

Clarus Therapeutics, Inc., a specialty pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women (“Clarus”), and Blue Water Acquisition Corp. (Nasdaq: BLUW), a publicly traded special purpose acquisition company (“Blue Water”), announced Thursday the completion of their previously announced business combination. Gross proceeds to Clarus Holdings from this business combination totaled approximately $25.3 million.

Premier, 11 Health Systems Acquire Minority Stake in Exela to Lock Down Drug Supply

In a bid to head off drug supply shortages, healthcare improvement company Premier Inc. and 11 of its partner health systems have acquired a minority stake in the holding company of Exela Pharma Sciences, the organizations announced Wednesday. The deal will see Premier’s health system members gain an uninterrupted supply of 19 pharmaceutical products developed and manufactured by the specialty pharma company at its Lenoir, North Carolina, location, according to the announcement. Of note, that includes Exela’s 503B pharmaceutical products and several injectables the companies said are often in short supply.

Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc.

Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) announced Wednesday that its shareholders have voted to approve the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) (“Xeris”). Upon close of the transaction, the business of Xeris and Strongbridge will be combined under an entity called Xeris Biopharma Holdings, Inc. (“Xeris Biopharma Holdings” or “HoldCo”).